Julien Hanson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/987610/publications.pdf

Version: 2024-02-01

68 papers	3,039 citations	218677 26 h-index	182427 51 g-index
72 all docs	72 docs citations	72 times ranked	5149 citing authors

#	Article	IF	Citations
1	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
2	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
3	An Autocrine Lactate Loop Mediates Insulin-Dependent Inhibition of Lipolysis through GPR81. Cell Metabolism, 2010, 11, 311-319.	16.2	291
4	Nicotinic acidâ€“ and monomethyl fumarateâ€“induced flushing involves GPR109A expressed by keratinocytes and COX-2â€“dependent prostanoid formation in mice. Journal of Clinical Investigation, 2010, 120, 2910-2919.	8.2	173
5	Coxibs and Cardiovascular Side-Effects: From Light to Shadow. Current Pharmaceutical Design, 2006, 12, 971-975.	1.9	118
6	Insight into SUCNR1 (GPR91) structure and function. , 2016, 159, 56-65.		110
7	Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends in Pharmacological Sciences, 2005, 26, 639-644.	8.7	90
8	Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends in Pharmacological Sciences, 2011, 32, 700-707.	8.7	83
9	The G protein-coupled receptors deorphanization landscape. Biochemical Pharmacology, 2018, 153, 62-74.	4.4	81
10	Deorphanization of GPR109B as a Receptor for the Î²-Oxidation Intermediate 3-OH-octanoic Acid and Its Role in the Regulation of Lipolysis. Journal of Biological Chemistry, 2009, 284, 21928-21933.	3.4	78
11	New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators. Current Medicinal Chemistry, 2004, 11, 1223-1241.	2.4	77
12	New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators. Current Medicinal Chemistry, 2004, 11, 1243-1252.	2.4	73
13	Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediatorsâ€”What is the Evidence so far?. Frontiers in Pharmacology, 2022, 13, 838782.	3.5	70
14	The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 2019, 8, 613.	4.1	60
15	From the Design to the Clinical Application of Thromboxane Modulators. Current Pharmaceutical Design, 2006, 12, 903-923.	1.9	58
16	The causes and consequences of pituitary gigantism. Nature Reviews Endocrinology, 2018, 14, 705-720.	9.6	57
17	Different contributions of chemokine Nâ€terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. British Journal of Pharmacology, 2018, 175, 1419-1438.	5.4	52
18	A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCRâ€“G protein interactions. Journal of Biological Chemistry, 2019, 294, 4079-4090.	3.4	48

#	Article	IF	Citations
19	Identification and pharmacological characterization of succinate receptor agonists. British Journal of Pharmacology, 2017, 174, 796-808.	5.4	46
20	7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency. Journal of Medicinal Chemistry, 2018, 61, 251-264.	6.4	41
21	Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds. Journal of Medicinal Chemistry, 2018, 61, 5279-5291.	6.4	41
22	Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A4. Biochemical Pharmacology, 2013, 85, 1795-1802.	4.4	37
23	Forskolin-free cAMP assay for Gi-coupled receptors. Biochemical Pharmacology, 2015, 98, 381-391.	4.4	37
24	Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7. Biochemical Pharmacology, 2016, 114, 14-21.	4.4	37
25	Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. , 2012, 136, 1-7.		35
26	Effect of BM-573 [N-Terbutyl-Nâ€²-[2-(4â€²-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 964-972.	2.5	34
27	Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists. Biochemical Pharmacology, 2018, 153, 299-309.	4.4	33
28	GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nature Communications, 2020, 11, 4752.	12.8	31
29	Pharmacological Characterization of N-tert-Butyl-Nâ€²-[2-(4â€²-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bleeding Time. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 499-505.	2.5	28
30	Activation of the Orphan G Proteinâ€“Coupled Receptor GPR27 by Surrogate Ligands Promotes Î²-Arrestin 2 Recruitment. Molecular Pharmacology, 2017, 91, 595-608.	2.3	27
31	Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig. Thrombosis Research, 2005, 116, 431-442.	1.7	21
32	Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis. Drug Discovery Today, 2017, 22, 702-711.	6.4	18
33	BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins and Other Lipid Mediators, 2011, 94, 124-132.	1.9	17
34	Partial filling affinity capillary electrophoresis as a useful tool for fragment-based drug discovery: A proof of concept on thrombin. Analytica Chimica Acta, 2017, 984, 211-222.	5.4	17
35	Pharmacological Profile and Therapeutic Potential of BMâ€573, a Combined Thromboxane Receptor Antagonist and Synthase Inhibitor. Cardiovascular Drug Reviews, 2005, 23, 1-14.	4.1	14
36	Design, Synthesis, and SAR Study of a Series of N-Alkyl-Nâ€˜-[2-(aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as Selective Antagonists of the TPÎ± and TPÎ² Isoforms of the Human Thromboxane A₂ Receptor. Journal of Medicinal Chemistry, 2007, 50, 3928-3936.	6.4	13

#	Article	IF	Citations
37	Progress in the Field of GPIIb/IIIa Antagonists. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2004, 2, 157-167.	1.7	13
38	In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-Nâ€²-[2-(4â€²-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 293-301.	2.5	12
39	Synthesis and Pharmacological Evaluation of Novel Nitrobenzenic Thromboxane Modulators as Antiplatelet Agents Acting on Both the Alpha and Beta Isoforms of the Human Thromboxane Receptor. Journal of Medicinal Chemistry, 2006, 49, 3701-3709.	6.4	12
40	New Developments on Thromboxane Modulators. Mini-Reviews in Medicinal Chemistry, 2004, 4, 649-657.	2.4	10
41	Capillary electrophoretic mobility shift displacement assay for the assessment of weak drug-protein interactions. Analytica Chimica Acta, 2018, 1034, 214-222.	5.4	10
42	Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27. European Journal of Medicinal Chemistry, 2021, 225, 113777.	5.5	9
43	BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2Î± in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandins and Other Lipid Mediators, 2007, 84, 14-23.	1.9	8
44	Alternative glycosylation controls endoplasmic reticulum dynamics and tubular extension in mammalian cells. Science Advances, 2021, 7, .	10.3	8
45	Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms. Current Drug Targets, 2018, 19, 1247-1255.	2.1	8
46	Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A2 receptor antagonists. European Journal of Medicinal Chemistry, 2013, 65, 32-40.	5.5	7
47	The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Frontiers in Immunology, 2022, 13, .	4.8	6
48	Nanoluciferase-Based Complementation Assay to Detect GPCR-G Protein Interaction. Methods in Molecular Biology, 2021, 2268, 149-157.	0.9	5
49	Effects of Dobutamine on Left Ventriculoarterial Coupling and Mechanical Efficiency in Acutely Ischemic Pigs. Journal of Cardiovascular Pharmacology, 2005, 45, 144-152.	1.9	4
50	Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family. , 2022, 240, 108217.		4
51	Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig. Prostaglandins and Other Lipid Mediators, 2005, 78, 82-95.	1.9	3
52	Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins and Other Lipid Mediators, 2006, 79, 53-73.	1.9	3
53	Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion. Experimental Physiology, 2007, 92, 127-137.	2.0	3
54	Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts. Future Medicinal Chemistry, 2022, 14, 899-913.	2.3	3

#	Article	IF	Citations
55	Update on GPIIb/IIIa antagonists. Expert Opinion on Therapeutic Patents, 2003, 13, 1173-1188.	5.0	2
56	GPCRs in immunity: Atypical receptors and novel concepts. Biochemical Pharmacology, 2016, 114, 1-2.	4.4	2
57	Dopamine D2L receptor density influences the recruitment of Î²-arrestin2 and Gi1 induced by antiparkinsonian drugs. Neuropharmacology, 2022, 207, 108942.	4.1	2
58	Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors. Prostaglandins and Other Lipid Mediators, 2004, 74, 75-86.	1.9	1
59	GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of G s and G q/11. FASEB Journal, 2021, 35, .	0.5	1
60	Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D_{2L} receptor. Fundamental and Clinical Pharmacology, 2022, 36, 976-984.	1.9	1
61	Effects of reperfusion on left ventricular hemodynamics and ventriculo-arterial coupling in acutely ischemic pigs. Computer Methods in Biomechanics and Biomedical Engineering, 2005, 8, 169-170.	1.6	0
62	BM-573, a thromboxane receptor antagonist, reduces development of atherosclerosis in apo E-deficient mice. Journal of Molecular and Cellular Cardiology, 2007, 42, S33-S34.	1.9	0
63	Î²â€arrestin2 recruitment at the Î²2 adrenergic receptor: A luciferase complementation assay adapted for undergraduate training in pharmacology. Pharmacology Research and Perspectives, 2021, 9, e00706.	2.4	0
64	NanoLuc (NLuc) complementation assay elucidates role of specific Gâ€proteins in GPR88 signaling. FASEB Journal, 2021, 35, .	0.5	0
65	Succinate receptor in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
66	GPR101 orphan receptor: a novel cause of growth hormone deregulation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-8-8.	0.0	0
67	GPR101 orphan receptor: a novel cause of growth hormone deregulation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, YIA-9.	0.0	0
68	Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0